常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.35/0.76
|
|
企業價值
15.21B
|
| 資產負債 |
|
每股賬面淨值
13.20
|
| 現金流量 |
|
現金流量率
0.03
|
| 損益表 |
|
收益
2.76B
|
|
每股收益
12.70
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/08 12:16 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, aliquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |

66.18 
